Related topics: Research management
As proof of microdosing's potential in drug development, bioanalytical CRO, Xceleron, is to lead the European Union Microdose AMS Partnership Programme (EUMAPP) having additionally been awarded €2.1 million to further develop this technology.
Copyright - Unless otherwise stated all contents of this web site are © 2000/2010 - Decision News Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department: Administration & Finance - Full details for the use of materials on this site can be found in the Terms & Conditions